Biogen Pharmachem Industries (531752) Q1 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 24/25 earnings summary
13 Jun, 2025Executive summary
Board approved unaudited financial results for the quarter ended June 30, 2024 at its August 1, 2024 meeting.
Financial highlights
Revenue from operations for Q1 FY25 was negative ₹9.09 lakhs, compared to ₹75.31 lakhs in Q1 FY24 and ₹77.93 lakhs in Q4 FY24.
Net loss for Q1 FY25 stood at ₹15.83 lakhs, versus net profit of ₹40.67 lakhs in Q1 FY24 and ₹74.14 lakhs in Q4 FY24.
Total expenses for Q1 FY25 were ₹6.73 lakhs, down from ₹34.64 lakhs in Q1 FY24 and up from ₹3.79 lakhs in Q4 FY24.
Earnings per share for Q1 FY25 was ₹(0.00), compared to ₹0.01 in Q4 FY24 and ₹0.03 in Q1 FY24.
Key financial ratios and metrics
Paid-up equity share capital remained at ₹6,526.03 lakhs.
Other equity as of March 31, 2024 was negative ₹873.99 lakhs.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biogen Pharmachem Industries
- Quarterly unaudited results approved with no material misstatements found by auditors.531752
Q1 26/27 - Revenue and net profit surged year-over-year, with a strong audit opinion and asset growth.531752Q4 25/26
- Board approved unaudited results for Q3 and nine months ended Dec 2025; no audit issues found.531752Q3 25/26
- Q2 FY26 saw a sharp revenue drop, net loss, and higher equity, with strong cash flows.531752Q2 25/26
- Revenue and net profit rebounded sharply year-over-year, with EPS turning positive.531752Q1 25/26
- Q2 FY25 saw Biogen Pharmachem swing to a net loss with declining income and equity.531752Q2 24/25
- Q3 FY25 saw a net loss and major board changes at Biogen Pharmachem Industries.531752Q3 24/25
- FY25 saw Biogen Pharmachem return to profit with robust revenue growth and capital inflow.531752Q4 24/25